SPDR Series Trust S&P Biotech (XBI)

$83.91 0.00 (0.00) Volume: 2,778,751 1:01AM EDT

Trading Data
Open $84.10
Volume 2,778,751
Day Low $83.55
Day High $84.18
52 Week Low $53.15
52 Week High $85.68
Fundamental Data
Market Cap (M) $4,141
Shares Outstanding 49,350,000
P/E Ratio 0.00
P/B Ratio 6.30
Dividend
Trailing 12-Month Dividend $0.00
Dividend Yield % 0.22
Latest Pay Date 2017-09-25
Frequency Quarterly

XBI Fundamental Charts

Historical TTM Price-to-Earnings for XBI
Historical TTM Price-to-Earnings without NRI for XBI
Historical Price-to-Book Ratio for XBI
Historical Dividend Yields for XBI

XBI Technical Indicators

Period Moving Average Price Change Percent Change Average Volume
5-Day -0.44% $-0.12 -0.14% 3,038,731
20-Day 0.43% $3.68 4.59% 3,443,351
50-Day 4.74% $5.6 7.15% 3,549,419
100-Day 9.41% $15.66 22.95% 3,997,213
200-Day 16.94% $21.97 35.47% 4,332,545
 
Period Relative Strength Percent R Average True Range Momentum
9-Day 56.693 -59.596 -59.596 0.03
14-Day 59.573 -59.596 -59.596 -0.71
20-Day 59.88 -26.577 -26.577 6.1
50-Day 58.444 -15.486 -15.486 4.84
100-Day 56.594 -9.306 -9.306 13.76

XBI Guru Trades

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Tepper 2017-06-30 New Buy0.38%$66.84 - $80.31 $ 83.9118%330,000
First Eagle Investment 2016-09-30 Sold Out $55.11 - $68.83 $ 83.9136%0
Premium More recent guru trades are included for Premium Members only!!
» Details

Guru Trades

Q3 2016

XBI Guru Trades in Q3 2016

Louis Moore Bacon 100,000 sh (unchged)
First Eagle Investment Sold Out
Steven Cohen 152,500 sh (-20.16%)
» More
Q4 2016

XBI Guru Trades in Q4 2016

Paul Tudor Jones 325,000 sh (New)
Steven Cohen 63,500 sh (-58.36%)
» More
Q1 2017

XBI Guru Trades in Q1 2017

Louis Moore Bacon 300,000 sh (New)
Steven Cohen 500,000 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q2 2017

XBI Guru Trades in Q2 2017

David Tepper 330,000 sh (New)
Louis Moore Bacon Sold Out
» More

XBI Headlines

Articles On GuruFocus.com
Value Investing in BioPharma Nov 18 2015 
Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

GF Chat

{{numOfNotice}}
FEEDBACK